New hope for Tough-to-Treat blood cancer: major trial tests promising drug combo

This study is testing whether adding a new immunotherapy drug called sugemalimab to standard chemotherapy works better than chemotherapy alone for adults with a rare and aggressive type of blood cancer (NK/T-cell lymphoma) that has returned or not responded to prior treatment. The main goal is to see if the combination helps patients live longer without their cancer getting worse. This is a large, late-stage trial designed to provide clear evidence on the treatment's effectiveness and safety.